Abstract
Sixty healthy nonresponders were randomized to receive intramuscular (IM) high dose hepatitis B virus (HBV) vaccine versus IM standard dose HBV vaccine plus granulocyte-macrophage colony-stimulating factor (GM-CSF) at 0-2 months. Antibody to hepatitis B surface antigen was measured 1 month after each dose and 3 months after the last dose. Two regimens were equivalent in eliciting seroprotection in nonresponders. Weight-height index (WHI) <39 and alanine transaminase (ALT) <39mg/dl predicted which nonresponders would seroconvert. A three-dose regimen of standard dose HBV vaccine plus GM-CSF may be a useful for seroprotection of healthy nonresponders.
Original language | English (US) |
---|---|
Pages (from-to) | 1174-1179 |
Number of pages | 6 |
Journal | Vaccine |
Volume | 21 |
Issue number | 11-12 |
DOIs | |
State | Published - Mar 7 2003 |
Keywords
- Granulocyte-macrophage colony-stimulating factor
- Hepatitis B virus vaccine
- Revaccination
ASJC Scopus subject areas
- Molecular Medicine
- Immunology and Microbiology(all)
- veterinary(all)
- Public Health, Environmental and Occupational Health
- Infectious Diseases